Park Soon-jae, founder and CEO of Alteogen, joins the three-comma club after his company announced a licensing deal with the U.S. drug giant.

As Concord and Blackstone vie to acquire the embattled song fund, Merck Mercuriadis' future with its investment adviser remains unclear. The cloudy future of Hipgnosis Songs Fund (HSF) became ...

Merck's experimental two-drug combination met the main goal of significantly suppressing replication of the HIV-1 virus in adults receiving another form of therapy in two late-stage studies, the ...